GlassScriptPhysician profile
Amaan Shafi
NPI 1548796329
$25,281.67
in general payments reported to CMS, 2019-2025
29 companies · $5,429 in 2025
The $5,429 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $6,692 · 2023: $10K · 2024: $2,551 · 2025: $5,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,031 · Travel and Lodging: $7,293 · Education: $1,156 · Grant: $500 · Entertainment: $84.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,030.96 |
| Travel and Lodging | $7,292.75 |
| Education | $1,155.90 |
| Grant | $500.00 |
| Entertainment | $84.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18,322.82 | 2021-2025 | Ensite Precision, Ensite, Cardiomems |
| Boston Scientific Corporation | $1,034.23 | 2023-2025 | General - Therapies, Watchman Flx, Watchman Access System |
| Abiomed | $976.09 | 2022-2024 | Impella |
| Biosense Webster, INC. | $733.77 | 2023-2025 | Carto 3, Visitag Surpoint External Processing Unit, Nuvision Ice Catheter |
| Biotronik INC. | $591.13 | 2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $547.59 | 2021-2025 | Lifevest |
| Medtronic, INC. | $424.25 | 2024-2025 | Micra, Evera Mri Xt Dr Surescan |
| Scpharmaceuticals INC. | $333.70 | 2023-2024 | |
| Lantheus Medical Imaging, INC. | $300.81 | 2021-2024 | Definity |
| Novo Nordisk INC | $249.06 | 2023-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $191.24 | 2023-2024 | Farxiga |
| Astellas Pharma US INC | $188.95 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $154.64 | 2022-2024 | Camzyos |
| Cvrx, INC. | $143.68 | 2022 | |
| Edwards Lifesciences Corporation | $131.38 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $123.55 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $121.81 | 2023 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $119.55 | 2022 | |
| Philips North America LLC | $105.88 | 2023 | (9520) Igt Devices Undivided |
| Merck Sharp & Dohme LLC | $99.97 | 2021-2024 | Verquvo |
| Stereotaxis INC | $84.34 | 2025 | Genesis |
| Chiesi USA, INC. | $83.64 | 2023 | Kengreal |
| Esperion Therapeutics, INC. | $42.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.79 | 2023 | |
| Livanova USA, INC. | $35.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.91 | 2023 | Jardiance |
| Cardiovascular Systems INC. | $25.37 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $24.16 | 2024 | Inpefa |
| Itamar Medical INC | $16.43 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amaan Shafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.